Foundational AI for for Collaborative Oncology Research

Workshop on Emerging opportunities/ technologies (e.g. Spatial transcriptomics, TCR)

Welcome to day 1, Opening

Roche Oncology Strategy and Pipeline Presentation followed by moderated panel

Poster 1 - imCORE Essentials

Poster 2 - Publications

Poster 3 - imCORE Portfolio

Poster 4 - Roche Pipeline

Poster 5 - imCORE RFPs 

Poster 6 - What is a Data Camp? 

Poster 7 - Spatial profiling identifies antigen-presenting CAFs as potential mediators of response to neoadjuvant immunotherapy in hepatocellular carcinoma 

Poster 8 - Visium HD spatial transcriptomics to uncover determinants of primary resistance to first-line chemo-immunotherapy in TLS-screened lung adenocarcinoma.

Poster 9 - Adaptive and innate immune cell infiltration are associated with relapse and prognosis after neoadjuvant chemotherapy in gastric and gastroesophageal junction adenocarcinoma. 

Poster 10 - Using single-cell sequencing to identify endothelial expression of immune checkpoint ligands in advanced hepatocellular carcinoma, pre- and post- atezolizumab plus bevacizumab.

Poster 11 - Immunomodulatory and anti-tumor effects of concurrent targeting of PD-1 and LAG-3 in human lung cancer

Poster 12 - Costimulation via CD19:4-1BB/L potentiates T-cell-engaging antitumor responses in preclinical DLBCL models. 

Poster 13 - Humanized-PDX models as a new tool to optimize anti-CCR8 Treg-targeting strategies. 

Poster 14 - A Multifocal hepatocarcinoma mouse model to test immunotherapy combinations.

Poster 15 - Identification of host factors and mechanism-based therapeutic combinations to enhance the antitumor potential of oncolytic viruses in pancreatic cancer. 

Poster 16 - MHC II-restricted neoantigen mRNA vaccine induces synergistic immune response for tumor rejection

Poster 17 - Multiplexed Engineering For Generation Of HLA-Class I Restricted CD4 T Cells

Poster 18 - Liver disease impact on immune responses in hepatocellular carcinoma

Poster 19 - Systemic neoantigen-specific CD8 T cells reveal central determinants of PD-(L)1 blockade efficacy.

Poster 20 - TRIM24 as a new target candidate to overcome plasticity dependent resistance to immunotherapy. 

Poster 21 - Loss of the Autoimmune Risk Gene TREX1 Reveals a Convergence of Mechanisms Promoting Immune Tolerance Loss and Antitumor Immunity
 

Poster 1 - Epigenetic Profiling of ctDNA for Non-Invasive Detection and Monitoring of Large B-Cell Lymphoma.

Poster 2 - Detection of minimal residual disease using cell-free DNA whole genome sequencing to guide maintenance therapy in high grade serous ovarian cancer. 

Poster 3 - Longitudinal Tracking of Tumor-Derived T-Cell Clonotypes via Plasma cfDNA in Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing Chemoradiotherapy and Immunotherapy. 

Poster 4 - Immune longitudinal profiling of the EORTC-1508GCG study reveals tertiary-lymphoid structures as key orchestrators of response to anti-PD-L1/anti-VEGF therapy in platinum-resistant ovarian cancer

Poster 5 - BEACON: A Phase II Study of Atezolizumab, Bevacizumab, and Cobimetinib in Patients with Recurrent, Platinum-Resistant, High Grade Serous Ovarian Cancer.

Poster 6 - Neoadjuvant atezolizumab in invasive, non-conventional urothelial carcinoma (UC): final analysis of the ABACUS-2 trial. 

Poster 7 - Clinical and translational results of the academic ARIANES Phase 2 basket study: Longitudinal bulk and single-cell RNAseq analyses... to PARP inhibitors and anti-PD-L1 therapy. 

Poster 8 - Microbiome and metabolome dynamics in melanoma patients receiving immunotherapy

Poster 9 - Real-world endpoints as surrogates for overall survival in metastatic bladder cancer. 

Poster 10 - Advancing cancer research through collaboration: WAYFIND-R´s approach to bridge clinical practice and research 

Poster 11 - Distributed Transcriptomic Modelling for Bias Identification and Biomarker Discovery in Immuno-Oncology.

Poster 12 - Harmonizing analytics across the immuno-oncology development pipeline